At AACR, there was talk of Chinese biotech's place in cancer research, oncology’s comms issue, and more.

The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...

Singapore’s Foreign Minister Vivian Balakrishnan said Wednesday that rising tensions in the Strait of Hormuz could serve as a ...

Nepal is about to miss the train of the biodigital revolution sweeping across the Global South. We cannot afford to sit back ...

Chief Scientific Officer Pedro Beltran will succeed Eli Wallace as CEO of BridgeBio Oncology Therapeutics, as the board eyes ...

But as the cost and complexity of drug development increases, the need for alternative sources of capital is becoming ...

Gubernatorial candidate Vivek Ramaswamy fielded questions about some of Ohio's hottest topics at a Turning Point USA event at ...

White Brook Capital Partners, an investment management firm, released its first-quarter 2026 investor letter. A copy of the ...

Today, as vice president and co-founder of power management company nGrid Energy, she is looking to change the system she ...

Art Hogan, Chief Market Strategist at B. Riley Wealth reveals why waiting for clarity is a mistake and why he still sees a ...

The AI revolution, led by companies like NVIDIA, is driving equity gains but poses significant economic and societal risks.

Every once in a while, an advance in treating cancer is so stunning that doctors get chills. Such is the case for Revolution Medicines’ pancreatic cancer therapy daraxonrasib, which in a late-stage ...